ClinicalTrials.gg
CompletedNCT06148272Updated Sep 21, 2026

A Study of LY3971297 in Healthy Participants

A Phase 1 interventional study of LY3971297 and Placebo in Healthy, Obesity and Hypertension, sponsored by Eli Lilly and Company. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
67th of 117
200 · median 267
Started
2023
with 20 others
Phase 1
40 of 118
8 open now
Registered
44th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 67th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 40 in phase 1, and was the 44th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.

03

Conditions studied

  • Healthy
  • Obesity
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination
  • For Parts A, B, C, E, and F: Have a screening (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening
  • For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China
  • For Part D, participants must have a stable dose of medications within the past 3 months prior to screening
  • For Part D, obesity BMI in the range of 30 to 40 kg/m², inclusive, with a waist circumference of at least 102 centimeter (cm) for men and at least 89 cm for women for participants of US sites only. For participants of Singaporean, South Asian, Japanese, and/or Chinese Origin at sites outside the US, the BMI range is 27 to 40 kg/m2 and the waist circumference is at least 90 cm for men and at least 80 cm for women
  • For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan
  • Male participants must agree to adhere to restrictions and female participants must be women not of
  • For Part G, have a screening BMI in the range of 18.5 to 40 kg/m², inclusive, with no significant weight gain or loss in the past 3 months prior to screening
  • For Part G, participants have a decreased estimated (eGFR)
  • For Parts D and G, participants are allowed to have stable background treatment for hypertension, type 2 diabetes mellitus (on oral drug therapy and/or long-acting insulin), dyslipidemia (on statin therapy) and/or hypothyroidism as determined by the investigator
  • For Part G, Participants should be on a stable dose of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker

Exclusion criteria

Exclusion Criteria:

  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Have known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation
  • Have blood pressure and/or pulse rate constituting a risk as determined by the investigator
  • Have a systolic blood pressure (BP) of less than 100 millimeters of mercury (mmHg)
  • Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position
  • For US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study
  • For Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening
  • Consume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine
  • Have alcohol intake that exceeds recommended alcohol consumption limits per local regulation or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge
  • For Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat)
  • For Parts D and G, has concurrent or anticipated use of long-acting nitrates or nitric oxide (NO) donors
  • For Part D, has current use of more than 3 mechanism of actions for treatment of hypertension
  • For Part G, has previous or current diagnosis of primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasm antibody-associated vasculitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    LY3971297 (Part A)

    Single ascending doses of LY3971297 administered subcutaneously (SC) in healthy participants

    Drug: LY3971297

  • Experimental
    LY3971297 (Part B)

    Multiple ascending doses of LY3971297 administered SC in healthy participants

    Drug: LY3971297

  • Experimental
    LY3971297 (Part C)

    Multiple ascending doses of LY3971297 administered SC in healthy Chinese participants

    Drug: LY3971297

  • Experimental
    LY3971297 (Part D)

    Multiple ascending doses of LY3971297 administered SC

    Drug: LY3971297

  • Experimental
    LY3971297 (Part E)

    Multiple doses of LY3971297 administered SC in healthy Japanese participants

    Drug: LY3971297

  • Placebo comparator
    Placebo (Part A, B, C, D, E, & G)

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3971297 (Part F)

    Single doses of LY3971297 administered intravenously (IV) in healthy participants

    Drug: LY3971297 IV

  • Experimental
    LY3971297 (Part G)

    Multiple doses of LY3971297 administered SC

    Drug: LY3971297

Interventions

  • DrugLY3971297

    Administered SC

  • DrugPlacebo

    Administered SC

  • DrugLY3971297 IV

    Administered IV

06

What researchers measure

Primary outcomes

  1. Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Part A and F: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline (Day of Exposure) to Day 29 post-dose

  2. Part B, C, D, E, & G: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Part B, C, D, E, \& G: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline (Day of Exposure) to Day 57 post-dose

  3. Part F: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297

    Part F: PK: AUC of LY3971297

    Time frame: Baseline Up to Day 29 post-dose for Part F

  4. Part F: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297

    Part F: PK: Cmax of LY3971297

    Time frame: Baseline Up to Day 29 post-dose for Part F

Secondary outcomes

  1. Part B, C, D, E, and G: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297

    Part B, C, D, E, and G: PK: AUC of LY3971297

    Time frame: Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G

  2. Part B, C, D, E, and G: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297

    Part B, C, D, E, and G: PK: Cmax of LY3971297

    Time frame: Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G

07

Study locations

7 sites
  • CenExel ACT
    Anaheim, California 92801, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33172, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
  • Hakata Clinic
    Fukuoka, 812-0025, Japan
  • P-One Clinic
    Hachiōji, 192-0071, Japan
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, 160-0004, Japan
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Aug 2026, 32 months.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 32 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 28, 2023
StartActual
Dec 7, 2023
Primary completionActual
Aug 18, 2026
CompletionActual
Aug 18, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06148272
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Dec 7, 2023
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026
Last update
Sep 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion